Digital health round-up: Pfizer appoints chief digital officer and morePfizer has appointed a chief digital officer because of the growing importance of digital technology in its R&D Share XDigital health round-up: Pfizer appoints chief digital officer and morehttps://pharmaphorum.com/views-and-analysis/digital-health-round-up-pfizer-appoints-chief-digital-officer-and-more/
Pfizer appoints chief digital officer in boardroom shakeupPfizer has appointed a chief digital officer because of the growing importance of digital technology in R&D and Share XPfizer appoints chief digital officer in boardroom shakeuphttps://pharmaphorum.com/news/pfizer-appoints-chief-digital-officer-in-boardroom-shakeup/
Pfizer’s leukaemia drug gets NHS funding in England and WalesPfizer’s Mylotarg has been approved by the English and Scottish NHS cost watchdogs as a restricted use treatment for Share XPfizer’s leukaemia drug gets NHS funding in England and Waleshttps://pharmaphorum.com/news/pfizers-leukaemia-drug-gets-nhs-funding-in-england-and-wales/
Lilly’s breast cancer drug Verzenio approved in EUEli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with Share XLilly’s breast cancer drug Verzenio approved in EUhttps://pharmaphorum.com/news/lillys-breast-cancer-drug-verzenio-approved-in-eu/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
Pfizer CEO Read to step down, COO Bourla takes the helmPfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January Share XPfizer CEO Read to step down, COO Bourla takes the helmhttps://pharmaphorum.com/news/pfizer-ceo-read-to-step-down-coo-bourla-takes-the-helm/
US regulator backs Pfizer’s Vizimpro lung cancer drugThe US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients Share XUS regulator backs Pfizer’s Vizimpro lung cancer drughttps://pharmaphorum.com/news/us-regulator-backs-pfizers-vizimpro-lung-cancer-drug/
Pharma depriving developing countries of taxes – reportA damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars’ worth Share XPharma depriving developing countries of taxes – reporthttps://pharmaphorum.com/news/pharma-depriving-developing-countries-of-taxes-report/
Pfizer/Merck KGaA eye fast review for kidney cancer comboA combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage Share XPfizer/Merck KGaA eye fast review for kidney cancer combohttps://pharmaphorum.com/news/pfizer-merck-kgaa-eye-fast-review-bavencio/
